NHI.no
Annonse
Informasjon

Influensa

Influensa er for de fleste ufarlig, men sykdommen kan være svært plagsom i perioden med feber og muskelverk. Risikogruppene bør vaksineres.

Influensa opptrer i epidemier og forekommer hyppigst i vintermånedene.

Sist oppdatert:

15. mai 2023

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Influensa . Referanselisten for dette dokumentet vises nedenfor

  1. Gaitonde DY, Moore FC, Morgan MK. Influenza: Diagnosis and Treatment. Am Fam Physician. 2019;100(12):751-758. PubMed
  2. Smittevern & Vaksine. Fakta om influensa. Folkehelseinstituttet, sist oppdatert 18.01.2022. www.fhi.no
  3. Hayward AC, Fragaszy EB, Bermingham A, et al. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. Lancet Respiratory Medicine 2014. doi:10.1016/S2213-2600(14)70034-7 DOI
  4. Folkehelseinstituttet. Vaksineanbefalinger influensasesongen 2022-2023. Sist oppdatert 27.06.2022. www.fhi.no
  5. European Centre for Disease Prevention and Control. Influenza virus characterisation - Summary Europe, March 2022. Published 21 Apr 2022. www.ecdc.europa.eu
  6. Paget J, Spreeuwenberg P, Charu V, et al. Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. J Glob Health. 2019;9(2):020421. PMID: 31673337 PubMed
  7. Taubenberger JK, Morens DM. Influenza: the once and future pandemic. Public Health Rep. 2010;125(suppl 3):16–26. PMID: 20568566 PubMed
  8. Abdelrahman Z, Li M, Wang X. Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses. Front Immunol. 2020;11:552909. Published 2020 Sep 11. PMID: 33013925 PubMed
  9. Peteranderl C, Herold S, Schmoldt C. Human influenza virus infections. Semin Respir Crit Care Med. 2016;37(4):487–500. PMID: 27486731 PubMed
  10. Dugas AF, Valsamakis A, Atreya MR, et al. Clinical diagnosis of influenza in the ED. Am J Emerg Med 2015 Jun; 33:770. PMID: 25827595 PubMed
  11. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No.: CD008965. DOI: 10.1002/14651858.CD008965.pub4 DOI
  12. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. Clin Infect Dis 2018. pmid:30566567 PubMed
  13. Centers for Disease Control and Prevention. Influenza Signs and Symptoms and the Role of Laboratory Diagnostics. Last updated August 31, 2020. www.cdc.gov
  14. Merckx J, Wali R, Schiller I, et al. Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Infection Compared With Reverse Transcriptase Polymerase Chain Reaction: A Systematic Review and Meta-analysis . Ann Intern Med 2017. pmid:28869986 PubMed
  15. Butler CC, van der Velden AW, Bongard E, et al. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet. 2019. PMID: 31839279 PubMed
  16. Hanula R, Bortolussi-Courval E, Mendel A, et al. Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients With Influenza A Systematic Review and Meta-analysis. JAMA Intern Med 2023. pmid:37306992 PubMed
  17. Center for Disease Control and Prevention. Maternal and infant outcomes among severely ill pregnant and postpartum women with 2009 pandemic influenza A (H1N1). MMWR 2011; 60: 1193-6. PubMed
  18. Louie JK, Lampiris H. Treating Influenza With Neuraminidase Inhibitors: What Is the Evidence? JAMA Intern Med. 2015 Dec;175(12):1899-900. PubMed
  19. Heneghan CJ, Onakpoya I, Joes MA, et al. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technol Assess 2016. PMID: 27246259 PubMed
  20. Dobson J, Whitley RJ, Pocock S, et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015. 385;1729-37. PMID: 25640810 PubMed
  21. Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014 9;348:g2545. doi: 10.1136/bmj.g2545. DOI
  22. Graner S, Smith T, Beau en pike-Michel C, et al. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study. BMJ 2017. PMID: 28246106 PubMed
  23. Hung IFN, To KKW, Chan JFW, et al. Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: An open-label randomized, controlled, phase IIb/III trial. Chest 2017 May; 151:1069. PMID: 27884765 PubMed
  24. Jefferson T, Del Mar C, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review. BMJ 2009; 339: b3675. PubMed
  25. Radonovich LJ Jr, Simberkoff MS, Bessesen MT, et al. N95 Respirators vs Medical Masks for Preventing Influenza Among Health Care Personnel: A Randomized Clinical Trial. JAMA. 2019 Sep 3;322(9):824-833. Pmid 31479137
  26. Folkehelseinstituttet. Vaksinasjonsveilederen. Effekt av influensavaksine. Informasjon om kunnskapsgrunnlaget. Sist oppdatert 22.06.2021. www.fhi.no
  27. Neuzil KM. An mRNA Influenza Vaccine - Could It Deliver?. N Engl J Med. 2023;388(12):1139-1141. PubMed
  28. Treanor JJ, Talbot HK, Ohmit SE, et al. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis 2012; 55: 951-9. PubMed
  29. Demicheli V, Jefferson T, Di Pietrantonj C, et al. Vaccines for preventing influenza in the elderly. Cochrane Database of Systematic Reviews 2018, Issue 2. The Cochrane Library
  30. Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for healthcare workers who care for people aged 60 or older living in long‐term care institutions. Cochrane Database of Systematic Reviews 2016, Issue 6. Art. No.: CD005187. DOI: 10.1002/14651858.CD005187.pub5. Accessed 11 January 2021. The Cochrane Library
  31. Ahmed F, Lindley MC, Allred N, et al. Effect of influenza vaccination of healthcare personnel on morbidity and mortality among patients: Systematic review and grading of evidence. Clin Infect Dis 2014 Jan 1; 58:50. doi.org/10.1093/cid/cit580
  32. Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews 2018, Issue 2. The Cochrane Library
  33. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews 2018, Issue 2. The Cochrane Library
  34. Håberg SE, Trogstad L, Gunnes N, et al. Risk of fetal death after pandemic influenza virus infection og vaccination. N Engl J Med 2013. doi: 10.1056/NEJMoa1207210 DOI
  35. Wang GF, Li W, Li K. Acute encephalopathy and encephalitis caused by influenza virus infection. Curr Opin Neurol. 2010;23(3):305-311. PMID: 20455276 PubMed
  36. Estabragh ZR, Mamas MA. The cardiovascular manifestations of influenza: a systematic review. Int J Cardiol. 2013 ;167(6):2397-403. doi: 10.1016/j.ijcard.2013.01.274. DOI
  37. Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. N Engl J Med 2020; 383: 2020. doi:10.1056/NEJMoa1915341 DOI
Annonse
Annonse